微創醫療(00853.HK)擬向微創視神注入資本
格隆匯 3 月 31日丨微創醫療(00853.HK)發佈公吿,2021年3月30日,微創視神、公司全資微創投資、望道通生物技術與投資者就有關增資訂立協議。微創投資、望道通生物技術與第二投資者各自同意向微創視神注資合計人民幣3.85億元。
微創視神現時為集團擁有70%權益的附屬公司,該公司主要專注於研發、生產和銷售用於診斷、治療及護理的眼科相關醫療產品,並提供相關服務。於本公吿日期及於增資完成後,微創視神為及將仍被視為公司的附屬公司。注入資本的金額乃參考微創視神在研發新技術及新產品以及商業化生產方面的工作的資金需要而釐定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.